4//SEC Filing
Hayon Yael 4
Accession 0001104659-23-093069
CIK 0001006281other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 4:30 PM ET
Size
8.6 KB
Accession
0001104659-23-093069
Insider Transaction Report
Form 4
Hayon Yael
VP, Research & Development
Transactions
- Award
Common Stock
2023-08-15+35,115→ 35,115 total(indirect: By Trust) - Award
Stock Options (Right to Buy)
2023-08-15+35,115→ 35,115 totalExercise: $1.99Exp: 2033-08-15→ Common Stock (35,115 underlying)
Footnotes (4)
- [F1]Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the "Plan"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
- [F3]The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
- [F4]Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeother
Related Parties
1- filerCIK 0001817121
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 4:30 PM ET
- Size
- 8.6 KB